Sunshine Biopharma, Inc.
SBFM
$1.51
-$0.04-2.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.93% | 41.58% | 67.29% | 54.08% | 94.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.93% | 41.58% | 67.29% | 54.08% | 94.94% |
| Cost of Revenue | 27.18% | 40.37% | 92.53% | 69.17% | 108.77% |
| Gross Profit | 20.44% | 44.01% | 20.67% | 28.78% | 72.22% |
| SG&A Expenses | 70.48% | 52.55% | 21.29% | 7.63% | -56.02% |
| Depreciation & Amortization | 54.25% | 73.66% | 45.85% | 22.77% | 123.16% |
| Other Operating Expenses | 41.67% | 7.41% | 50.93% | 19.15% | 39.13% |
| Total Operating Expenses | 31.19% | 41.63% | 60.79% | 32.26% | -1.22% |
| Operating Income | -71.64% | -41.94% | -25.09% | 26.16% | 76.43% |
| Income Before Tax | -122.07% | -60.95% | -2.90% | 23.84% | 95.58% |
| Income Tax Expenses | -158.42% | 424.88% | -491.90% | -51.62% | -5.57% |
| Earnings from Continuing Operations | -72.66% | -83.85% | 45.21% | 24.59% | 94.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.66% | -83.85% | 45.21% | 24.59% | 94.68% |
| EBIT | -71.64% | -41.94% | -25.09% | 26.16% | 76.43% |
| EBITDA | -72.27% | -40.33% | -24.35% | 27.10% | 77.18% |
| EPS Basic | 98.83% | 98.14% | 86.03% | 74.09% | 95.91% |
| Normalized Basic EPS | 98.50% | 98.37% | 73.77% | 73.83% | 84.02% |
| EPS Diluted | 98.83% | 98.14% | 86.03% | 74.10% | 95.91% |
| Normalized Diluted EPS | 98.50% | 98.37% | 73.77% | 73.83% | 84.02% |
| Average Basic Shares Outstanding | 14,735.17% | 9,803.13% | 291.34% | 191.82% | 29.46% |
| Average Diluted Shares Outstanding | 14,735.17% | 9,803.13% | 291.34% | 191.82% | 29.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |